Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Lomitapide in Pediatric HoFH
NCT02765841Phase 3Withdrawn
- Sponsor
- Aegerion Pharmaceuticals
- Start
- May 2016
- Primary completion
- Mar 2017
- Modality
- Small Molecules
01
Overview
A Phase 3 trial of lomitapide in homozygous familial hypercholesterolemia (HoFH), sponsored by Aegerion Pharmaceuticals. Planned start May 2016; status: withdrawn.
02
Drugs
lomitapide
03
Conditions
homozygous familial hypercholesterolemia (HoFH)
Beyond the preview
Go deeper on NCT02765841.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02765841.